Do different clinical evidence bases lead to discordant health-technology assessment decisions? An in-depth case series across three jurisdictions

Overview of attention for article published in ClinicoEconomics and Outcomes Research: CEOR, January 2013

Altmetric Badge

Mentioned by

twitter: 1 X user

Citations

dimensions_citation: 23 Dimensions

Readers on

mendeley: 70 Mendeley

Summary X Dimensions citations

So far, Dimensions has found 23 publications that cite this research output.

23

The most recent citing publications are shown below. View all 23 publications that cite this research output on Dimensions.

The reimbursement process in three national healthcare systems: variation in time to reimbursement of pembrolizumab for metastatic non-small cell lung cancer

Article in Journal of Pharmaceutical Policy and Practice (December 2023)

Assessment of FDA-Approved Drugs Not Recommended for Use or Reimbursement in Other Countries, 2017-2020

Article in JAMA Internal Medicine (April 2023)

Appraisals by Health Technology Assessment Agencies of Economic Evaluations Submitted as Part of Reimbursement Dossiers for Oncology Treatments: Evidence from Canada, the UK, and Australia

Article in Current Oncology (October 2022)